Stockscreener 앱 받기
38.54
2.86%
1.07
시간 외 거래:
38.54
전일 마감가:
$37.47
열려 있는:
$37.8
하루 거래량:
605.84K
Relative Volume:
1.25
시가총액:
$1.68B
수익:
$384.10M
순이익/손실:
$-9.07M
주가수익비율:
-275.29
EPS:
-0.14
순현금흐름:
$11.10M
1주 성능:
-2.26%
1개월 성능:
+0.13%
6개월 성능:
+39.39%
1년 성능:
+79.42%
1일 변동 폭
$37.47
$39.28
1주일 범위
$36.56
$39.43
52주 변동 폭
$17.82
$42.05
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
Kiniksa Pharmaceuticals International Plc
전화
(781) 431-9100
주소
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
38.54 | 2.84B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
124.46 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 42.40B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.32 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.46 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.33 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-29 | 개시 | TD Cowen | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2024-05-03 | 개시 | Wells Fargo | Overweight |
| 2020-06-29 | 재확인 | BofA Securities | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-12-12 | 재확인 | Wedbush | Outperform |
| 2018-06-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2025 Earnings Call Transcript - Insider Monkey
Y Intercept Hong Kong Ltd Buys New Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Asset Management One Co. Ltd. Boosts Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Equities Analysts Offer Predictions for KNSA FY2025 Earnings - MarketBeat
Kiniksa raises 2025 ARCALYST sales guidance to $670M-$675M as market penetration grows - MSN
Ragosa Mark, CFO of Kiniksa, sells $4100 in KNSA stock By Investing.com - Investing.com Australia
Ragosa Mark, CFO of Kiniksa, sells $4100 in KNSA stock - Investing.com
New Strong Sell Stocks for Oct. 30th - The Globe and Mail
Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage - Seeking Alpha
Goldman Sachs Raises Target Price for Kiniksa Pharmaceuticals (K - GuruFocus
Kiniksa Pharmaceuticals International’s (KNSA) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Kiniksa Pharmaceuticals (KNSA): Assessing Valuation After Strong ARCALYST Growth, Raised Guidance, and FDA Orphan Drug Win - Yahoo! Finance UK
Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates - sharewise.com
Kiniksa Pharmaceuticals International, plc SEC 10-Q Report - TradingView
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month HighHere's Why - MarketBeat
Kiniksa Ramps Up Revenue Forecast As ARCALYST Gains Traction - Finimize
KNSA Projects Annual Cash Flow Positivity with Current Plan - GuruFocus
KNSA Surpasses Revenue Expectations and Updates Sales Forecast - GuruFocus
Kiniksa Pharmaceuticals Swings to Q3 Net Income, Revenue Increases - MarketScreener
Kiniksa Pharmaceuticals Q3 2025 Earnings: Revenue Surpasses Esti - GuruFocus
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q3 EPS $0.23, vs. FactSet Est of $0.32 - MarketScreener
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results - TradingView
Kiniksa Pharma raises ARCALYST's 2025 sales forecast - MarketScreener
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution - The Manila Times
Peregrine Capital Management LLC Trims Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals Hits New 52-Week High of $39.60 - Markets Mojo
Earnings To Watch: Kiniksa Pharmaceuticals International PLC (KNSA) Reports Q3 2025 Result - Yahoo Finance
Earnings To Watch: Kiniksa Pharmaceuticals International PLC (KN - GuruFocus
Allspring Global Investments Holdings LLC Sells 29,796 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
Michael Megna Sells 50,490 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 121,248 Shares of Stock - MarketBeat
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025 - The Manila Times
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 97,390 Shares of Stock - MarketBeat
Kiniksa Pharma CEO Patel sells $10 million in shares By Investing.com - Investing.com Nigeria
Kiniksa Pharma CEO Patel sells $10 million in shares - Investing.com India
Kiniksa Pharmaceuticals (KNSA): Investor Outlook on a 29% Upside Potential in the Biopharma Space - DirectorsTalk Interviews
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month High After Analyst Upgrade - Defense World
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Citigroup Boosts Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target to $50.00 - Defense World
Cannon Global Investment Management LLC Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
FDA grants orphan drug designation to Kiniksa’s pericarditis treatment By Investing.com - Investing.com Canada
Eben Tessari Sells 12,368 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals (KNSA) Sees 11% Increase in Citigroup's Price Target | KNSA Stock News - GuruFocus
FDA grants orphan drug designation to Kiniksa’s pericarditis treatment - Investing.com
Kiniksa (KNSA) Receives FDA Orphan Drug Status for Pericarditis Treatment - GuruFocus
Kiniksa Pharmaceuticals Says Pericarditis Treatment Candidate Got US FDA Orphan Drug Designation - MarketScreener
Kiniksa Pharmaceuticals Receives Orphan Drug Designation from FDA for KPL-387 in Treating Pericarditis - Quiver Quantitative
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis - GlobeNewswire
Kiniksa Pharma COO Tessari sells $465,843 in shares By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.60%
0.45%
자본화:
|
볼륨(24시간):